Daiwa analyst Narumi Nakagiri downgraded Johnson & Johnson to Neutral from Outperform with a price target of $150, down from $160. The analyst is concerned about intensifying competition in medical sales. The firm expects lower medical device prices and higher tax rates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target lowered to $155 from $160 at Goldman Sachs
- Johnson & Johnson price target lowered to $185 from $195 at TD Cowen
- Johnson & Johnson price target raised to $169 from $167 at Morgan Stanley
- Stock Market News Today, 7/17/24 – Nasdaq Sinks Almost 3%; Housing Data Beats Estimates
- Johnson & Johnson price target raised to $160 from $155 at Stifel
